Moxifloxacin Tablet is indicated for the treatment of the following infections: Acute bacterial sinusitis, Acute exacerbation of chronic bronchitis, Community-acquired pneumonia, Uncomplicated and complicated skin and skin structure infections, Complicated intra-abdominal infections, Pelvic inflammatory disease.

Moxifloxacin is a fourth-generation synthetic broad-spectrum antibacterial agent belonging to the fluoroquinolone class. It is active against a wide range of gram-positive, gram-negative, anaerobic, and atypical bacteria, including Mycoplasma pneumoniae. Moxifloxacin exerts its antibacterial effect by inhibiting topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential for bacterial DNA replication, transcription, and repair.

The recommended dose of Moxifloxacin Tablet is 400 mg once daily. The duration of treatment depends on the type of infection, as follows:

• Acute bacterial sinusitis: 400 mg once daily for 7–10 days
• Acute bacterial exacerbation of chronic bronchitis: 400 mg once daily for 5–10 days
• Community-acquired pneumonia: 400 mg once daily for 7–14 days
• Uncomplicated skin and skin structure infections: 400 mg once daily for 7 days
• Complicated skin and skin structure infections: 400 mg once daily for 7–21 days
• Complicated intra-abdominal infections: 400 mg once daily for 5–14 days
• Pelvic inflammatory disease: 400 mg once daily for 14 days

The absorption of Moxifloxacin may be reduced when it is taken together with antacids, sucralfate, multivitamins, or products containing multivalent cations such as iron or zinc. Moxifloxacin may also increase the risk of convulsions when used with nonsteroidal anti-inflammatory drugs (NSAIDs) and may enhance the risk of bleeding when used concomitantly with warfarin. Therefore, caution is advised and concomitant use should be avoided whenever possible.

Moxifloxacin is contraindicated in patients with a known history of hypersensitivity to Moxifloxacin or other quinolone antibacterial agents.

Common side effects of Moxifloxacin include nausea, vomiting, diarrhea, headache, and dizziness.

US FDA Pregnancy Category C. Moxifloxacin is not recommended for use during pregnancy or during lactation.

Moxifloxacin may increase the risk of tendinitis and tendon rupture. Treatment should be discontinued if pain, swelling, or inflammation of a tendon occurs. Moxifloxacin should not be used in patients with known prolongation of the QT interval, in patients with uncorrected hypokalemia, or in those receiving Class IA or Class III antiarrhythmic agents.

Patients with renal or hepatic impairment: No dosage adjustment is required in patients with renal or hepatic impairment.

Pediatric patients: The safety and effectiveness of Moxifloxacin have not been established in children and adolescents under 18 years of age.

4-Quinolone preparations

Store in a dry place, protected from light and heat. Keep out of the reach of children.